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Background
T cells targeting unique somatic mutations appear to play
an important role in the antitumor responses observed
following T cell transfer, and isolation of mutation-specific
lymphocytes and T-cell receptors has become a major
obstacle to the development of more effective immu-
notherapies. The detection of tumor-reactive and muta-
tion-specific cells in patients with cancer has been largely
restricted to tumor-infiltrating lymphocytes, but mutation-
specific cells are thought to be far less prevalent in periph-
eral blood, a more accessible and abundant source of
T cells. We recently reported that expression of PD-1
identifies the patient-specific repertoire of tumor-reactive
cells infiltrating melanoma tumors. Given these findings,
we explored the utility of PD-1 expression on peripheral
blood lymphocytes to detect and enrich for tumor and
neoantigen specific lymphocytes.
Methods
To this end, peripheral blood CD8+ lymphocytes were
separated based on the expression of PD-1 into
CD8+PD-1- and CD8+PD-1+ and CD8+PD-1hi cells,
and expanded in vitro for 15 days. Circulating T cell
subsets were subsequently screened for recognition of
mutated antigens identified by whole exome sequencing
using a high throughput and personalized approach that
enables the expression of all the potential tumor neoan-
tigens in the autologous antigen-presenting cells. In
addition, recognition of shared melanoma differentiation
antigens and cancer germline antigens was also
evaluated.
Results
PD-1+ lymphocytes represented a small percentage of
all the circulating CD8+ cells in patients with metastatic
melanoma. We found that selection of CD8+PD-1+ lym-
phocytes circulating in peripheral blood, but not the
CD8+ or CD8+PD-1- cells, led to direct enrichment of
tumor-reactive cells from peripheral blood in all four
patients studied. In three out of four melanoma patients,
the peripheral blood CD8+PD-1+ and PD-1hi cells con-
tained mutation-specific lymphocytes targeting 3, 3 and
1 unique patient-specific neoantigens, respectively. In
addition, circulating CD8+PD- 1+ and PD-1hi lympho-
cytes from all four patients evaluated were also enriched
in T cells targeting at least one cancer germline antigen,
including NY-ESO-I, MAGE-A3, and SSX2. Neither
mutation-specific nor cancer germline-specific lympho-
cytes were detected in the peripheral blood CD8+ or the
CD8+PD-1- populations.
Conclusion
Our findings provide evidence that peripheral blood
CD8+PD-1+ from cancer patients are enriched in natu-
rally-occurring tumor-reactive and mutation-specific cells
and provide a novel strategy to develop personalized T cell
based therapies to treat cancer.
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